India, June 3 -- Biocon has announced that it has received approval from the Drugs Controller General of India (DCGI), under the Central Drugs Standard Control Organisation (CDSCO), for its Liraglutide drug substance.
In addition, Biocon's wholly owned subsidiary, Biocon Pharma, has also obtained CDSCO approval for the Liraglutide drug product—a 6 mg/ml solution for injection available in pre-filled pens and cartridges. This approval pertains to the generic version of Victoza, indicated for the treatment of type 2 diabetes mellitus in adults, adolescents, and children aged 10 and above who have not achieved adequate glycemic control with diet and exercise alone. The approval was granted under the recently introduced 101 route, which ...